

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

AITKEN ET AL.

APPLICATION NO: 10/550,381

FILED: SEPTEMBER 21, 2005

FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



Daniel J. Woods
Attorney for Applicants
Reg. No. 59,864

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9587

Date:

2/17/09